



14<sup>th</sup> October 2024

The Secretary,  
Bombay Stock Exchange Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street,  
Mumbai – 400 001  
Scrip Code: 544250

The Secretary,  
The National Stock Exchange of India Limited  
C-1, Block G, Exchange Plaza  
Bandra-Kurla Complex  
Bandra East, Mumbai - 400 050  
Symbol: SANOFICONR

**Sub: Disclosure under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.**

Dear Sir/Ma'am,

Pursuant to SEBI (Prohibition of Insider Trading) Regulations, please find attached the disclosure received from Opella Healthcare Participations BV (“Opella”) regarding its status as a Promoter of the Company. The Company received this disclosure from Opella on 11<sup>th</sup> October 2024.

Kindly take the above information on record.

Thanking you,

Yours faithfully,  
For **Sanofi Consumer Healthcare India Limited**

---

**Nikunj Kumar Savaliya**  
**Company Secretary and Compliance Officer**  
**Membership No.: FCS 7048**

**Encl. a. a.**

# Opella.

Date: 11 October 2024

To,

Sanofi Consumer Healthcare India Limited,  
3<sup>rd</sup> Floor,  
Sanofi House,  
CTS No. 117-B, L&T Business Park,  
Saki Vihar Road, Powai,  
Mumbai – 400072

**Re.: Disclosure under Regulation 7(1)(b) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (“PIT Regulations”).**

Dear Sir / Ma’am,

This is in reference to the prior intimation made by Opella Healthcare Participations BV (“Opella”) to the stock exchanges (namely BSE Limited and National Stock Exchange of India) under Regulation 10(5) of the Takeover Relations on 3 October 2024 informing you about the proposed inter-se transfer of equity shares of Sanofi Consumer Healthcare India Limited (“SCHIL”), between Hoechst GmbH and Sanofi (existing promoters of SCHIL, collectively the “Sellers”) and Opella (“Acquirer”/“Buyer”), to be undertaken in one or more tranches.

In this connection, we now wish to inform you that, we, Opella acquired 1,39,04,722 equity shares in SCHIL (representing 60.37% of the equity share capital of SCHIL) from Hoechst GmbH on 10 October 2024. The said inter-se transfer was undertaken on-market of the BSE Limited stock exchange.

Please find enclosed the disclosure in respect of the aforesaid sale.

# Opella.

**For and on behalf of Opella Healthcare Participations B.V**



**Authorized Signatory**

**Name:** Peter Brouwer

**Designation:** Director

**Date:** 11 October 2024

**Place:** Amsterdam, the Netherlands

# Opella.

**SEBI (Prohibition of Insider Trading) Regulations, 2015 [Regulation 7 (1) (b)  
read with Regulation 6(2) – Disclosure on becoming a Key Managerial  
Personnel/Director/Promoter/Member of the promoter group]**

Name of the company: Sanofi Consumer Healthcare India Limited (“SCHIL”)

ISIN of the company: INE0UOS01011

**Details of Securities held on appointment of Key Managerial Personnel (KMP) or Director or upon becoming a Promoter or member of the promoter group of a listed company and immediate relatives of such persons and by other such persons as mentioned in Regulation 6(2).**

Name, PAN, CIN/DIN & Address with contact nos.	Category of Person (KMP / Director or Promoter or member of the promoter group /Immediate relative to/others etc.)	Date of appointment of KMP/ Director OR Date of becoming Promoter/ member of the promoter group	Securities held at the time of appointment of KMP/Director or upon becoming Promoter or member of the promoter group		% of Shareholding
			Type of security (For eg. – Shares, Warrants, Convertible Debentures, Rights entitlements, etc.)	No.	
1	2	3	4	5	6
<b>Name:</b> Opella Healthcare Participations B.V. (“Opella”)  <b>PAN:</b> AAECO4323P  <b>CIN:</b> <i>Not applicable</i>  <b>Address:</b> Paasheuvelweg 25, 1105 BP	Promoter	10 October 2024	Equity Shares	1,39,04,722	60.37%

# Opella.

Amsterdam, the Netherlands					
<b>Contact No.:</b> +31 202453321					

*Note: "Securities" shall have the meaning as defined under regulation 2(1)(i) of SEBI (Prohibition of Insider Trading) Regulations, 2015.*

**Details of Open Interest (OI) in derivatives on the securities of the company held on appointment of KMP or Director or upon becoming a Promoter or member of the promoter group of a listed company and immediate relatives of such persons and by other such persons as mentioned in Regulation 6(2).**

Open Interest of the Future contracts held at the time of appointment of Director/KMP or upon becoming Promoter/member of the promoter group			Open Interest of the Option Contracts held at the time of appointment of Director/KMP or upon becoming Promoter/member of the promoter group		
Contract specifications	Number of units (contracts * lot size)	Notional value in Rupee terms	Contract specifications	Number of units (contracts * lot size)	Notional value in Rupee terms
7	8	9	10	11	12
Not applicable ("N.A.")	N.A.	N.A.	N.A.	N.A.	N.A.

*Note: In case of Options, notional value shall be calculated based on premium plus strike price of options*

